Schilke Tobin

CIK 00016789841 companyNASHVILLE, TN

Transactions

Companies

Filings

CIK

0001678984

Recent Transactions

16 trades

Sale
Revance Therapeutics, Inc.
Common Stock
2023-06-02$31.00/sh−500→ 80,828 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-06-01$30.57/sh−2,701→ 81,328 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-02-01$34.60/sh−3,201→ 54,676 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-02-01$34.60/sh−3,201→ 54,676 total
Award
Revance Therapeutics, Inc.
Employee Stock Option (Right to Buy)
2023-01-31+50,435→ 50,435 total
Award
Revance Therapeutics, Inc.
Employee Stock Option (Right to Buy)
2023-01-31+50,435→ 50,435 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-01-20$31.00/sh−1,000→ 57,877 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-01-20$31.00/sh−1,000→ 57,877 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-01-20$31.00/sh−1,000→ 57,877 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-01-20$31.00/sh−1,000→ 57,877 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-01-20$31.00/sh−1,000→ 57,877 total
Sale
Revance Therapeutics, Inc.
Common Stock
2023-01-20$31.00/sh−1,000→ 57,877 total
Award
Revance Therapeutics, Inc.
Common Stock
2022-12-31$12.18/sh+645→ 62,578 total
Award
Revance Therapeutics, Inc.
Common Stock
2022-12-31$12.18/sh+645→ 62,578 total
Award
Revance Therapeutics, Inc.
Common Stock
2022-12-31$12.18/sh+645→ 62,578 total
Award
Revance Therapeutics, Inc.
Common Stock
2022-12-31$12.18/sh+645→ 62,578 total

C/O REVANCE THERAPEUTICS, INC. 1222 DEMONBREUN STREET, 20TH FLOOR

NASHVILLE, TN, 37203